Tested treatment with tiny lung particles for moderate to severe ARDS
Part of Lungs & breathing clinical trials.
This Phase 3 trial studies an “extracellular vesicle” treatment in people with moderate to severe ARDS, a serious lung breathing problem. The goal is to see whether the treatment can improve outcomes compared with standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 75 years old
- Be diagnosed with moderate to severe ARDS within 24 hours before the first infusion
- ARDS started within 7 days of a known trigger (or symptoms are rapidly worsening) and affect both lungs
- Have significant breathing failure requiring breathing support (like CPAP/PEEP or high-flow oxygen) with specific settings
- Not be connected to a heart-lung machine called ECMO when screening starts
- Be able to consent and agree to follow study procedures for the full study period
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (LEAF-4L6715) for people with acute respiratory distress syndrome (ARDS), a serious lung condition. The aim is to see if this medicine helps improve breathing and recovery in people on a breathing machine. The trial is for adults who have had ARDS for at least 24 hours and are already on a breathing machine.
This trial is testing new treatments for people with ARDS, a serious lung condition. The goal is to find therapies that help patients breathe better and recover faster. If you or a loved one has ARDS, this study may offer access to experimental treatments.
This trial tests whether an injection of stem cells from umbilical cords can help people with severe ARDS (a type of lung failure) recover faster. It is for those who have not improved after standard treatment and whose ARDS is caused by an infection (not COVID-19).
This study tests an “extra-CO2 removal” breathing support approach to help protect the lungs in people with moderate ARDS, a serious lung injury. You would be on a ventilator for a short time, and the team would check whether this approach improves breathing outcomes while aiming to be safer for the lungs.
This trial tests whether erythropoietin (EPO), a medicine that affects red blood cell production, can help clear extra fluid from the lungs in people with acute respiratory distress syndrome (ARDS). If it works, it could improve breathing and reduce lung fluid buildup during critical illness.
This study looks at a specific breathing event (“avalanche phenomenon”) when the lungs are opened in people with early, moderate-to-severe ARDS. The goal is to understand what’s happening in the lungs and whether it can guide better care.
Hear when a new Acute Respiratory Distress Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.